Thryv Therapeutics

Thryv Therapeutics Inc., formerly known as LQT Therapeutics Inc., is a privately held company based in Montreal, Quebec, Canada. Since 2019, they have been pioneering a precision medicine approach to treating Long QT Syndrome through SGK-1 inhibition and have since expanded their portfolio to include treatment for drug-resistant and rare cancers. The development of SGK-1 inhibitors represents a novel approach to targeting refractory cancers and complements existing therapies.